<DOC>
	<DOCNO>NCT01802918</DOCNO>
	<brief_summary>GSK2838232 novel human immune virus ( HIV ) maturation inhibitor develop treatment chronic HIV infection . This study first administration GSK2838232 human establish initial safety , tolerability , pharmacokinetic profile follow single dos GSK2838232 evaluate effect food ritonavir ( RTV ) GSK2838232 healthy subject . There 2 cohort study . In Cohort 1 , approximately 8 healthy subject enrol ( 6 active 2 placebo ) dose visit . There four dosing session subject subject randomize receive placebo random sequence . In Cohort 2 , approximately 8 healthy subject enrol ( 6 active dos 2 placebo dos dose visit ) . Cohort 2 four dosing session subject subject randomize receive placebo random sequence .</brief_summary>
	<brief_title>Single Dose Escalation Study GSK2838232 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Inclusion Criteria Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinically significant abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure Male female 18 50 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone &gt; 40 milli international unit [ MlU ] /milliliter [ mL ] estradiol &lt; 40 picogram [ pg ] /mL [ &lt; 147 picomoles /liter ] confirmatory ) . Body weight &gt; = 50 kilogram ( kg ) ( 110 pound . ) men &gt; = 45 kg ( 99 pound ) woman body mass index ( BMI ) within range 18.5 31.0 kg/meter^2 ( inclusive ) . A Creatinine clearance ( CLcr ) &gt; 80 mL/minute ( min ) determine CockcroftGault equation . CLcr ( mL/min ) = ( 140 age ) x weight / ( 72 x serum creatinine [ Scr ] ) ( time 0.85 female ) age year , weight kg , Scr unit milligram ( mg ) /deciliter ( dL ) . Male subject female partner childbearing potential must agree use contraception method . This criterion must follow time first dose study medication follow visit . Subject must capable give write informed consent , include compliance requirement restriction list consent form . Exclusion Criteria A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &gt; = 1.5x Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent ) . Screening baseline cardiac troponin I great 99 percent cutoff ( &gt; .045 nanogram [ ng ] /mL Dimension Vista cardiac troponin I [ CTNI ] assay ) . Screening BNP great upper limit normal Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test Human Immuno Virus antibody . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive urine serum human chorionic gonadotropin ( hCG ) test screen prior dose Day 1 . Lactating female . History sensitivity heparin heparininduced thrombocytopenia . Subjects asthma history asthma A history regular use tobacco nicotinecontaining product within 6 month prior screen . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . Exclusion Criteria 24Hour Screening Holter : symptomatic arrhythmia ( except isolate extra systole ) , sustain cardiac arrhythmia ( atrial fibrillation flutter , supraventricular tachycardia ( &gt; =10 consecutive beat ) , complete heart block ) , nonsustained sustain ventricular tachycardia ( define &gt; = 3 consecutive ventricular ectopic beat ) , conduction abnormality ( include specific leave right incomplete complete bundle branch block , atrioventricular ( AV ) block [ 2nd degree high ] , WolffParkinsonWhite [ WPW ] syndrome etc . ) , sinus Pauses &gt; 3 second , 300 supraventricular ectopic beat 24 hour , 250 ventricular ectopic beat 24 hour . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) : Male subject Heart rate &lt; 45 &gt; 100 beat per minute ( bpm ) female subject heart rate &lt; 50 &gt; 100 bpm , PR &lt; 120 &gt; 220 millisecond ( msec ) , QRS duration &lt; 70 &gt; 120 msec , QT interval correct heart rate ( Fridericia 's ) &gt; 450 msec . ( Note : A heart rate 100 110 bpm rechecked ECG vitals within 30 minute verify eligibility ) . Evidence previous myocardial infarction ( Does include ST segment change associate repolarization ) . Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , WPW syndrome ) . Sinus Pauses &gt; 3 second . Any significant arrhythmia , opinion principal investigator OR GSK medical monitor , interfere safety individual subject . Nonsustained sustain ventricular tachycardia ( &gt; =3 consecutive ventricular ectopic beat ) . Medical history cardiac arrhythmia cardiac disease family personal history long QT syndrome . Any clinically significant abnormal echocardiogram finding . Abnormal echocardiogram finding discuss Medical Monitor prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>single dose</keyword>
	<keyword>HIV</keyword>
	<keyword>maturation inhibitor</keyword>
	<keyword>GSK2838232</keyword>
	<keyword>FTIH</keyword>
	<keyword>healthy subject</keyword>
</DOC>